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AbstrACt
Objectives To describe the prevalence, incidence and 
surgical management of carpal tunnel syndrome (CTS), 
between 1993 and 2013, as recorded in the Clinical 
Practice Research Datalink (CPRD).
Design We completed a series of cross-sectional 
epidemiological analyses to observe trends over time.
setting Primary care data collected between 1993 and 
2013, stored in the CPRD.
Population Individuals aged ≥18 years were selected. 
Prevalent and incident episodes of CTS and episodes 
of surgical intervention were identified using a list of 
preidentified Read codes.
Analysis We defined incident episodes as those with no 
preceding diagnostic code for CTS in the past 2 years of 
data. Episodes of surgery were expressed as a percentage 
of the prevalent population during the same calendar year. 
Joinpoint regression was used to determine significant 
changes in the underlying trend.
results The prevalence of CTS increased over the study 
period, with a particular incline between 2000 and 2004 
(annual percentage change 7.81). The female-to-male 
prevalence ratio reduced over time from 2.74 in 1993 
to 1.93 in 2013. The median age of females and males 
with CTS were noted to increase from 49 and 53 years, 
respectively in 1993 to 54 and 59 years, respectively in 
2013. Incidence was also noted to increase over time. 
After an initial increase between 1993 and 2007, the 
percentage of prevalent patients with a coded surgical 
episode began to decrease after 2007 to 27.41% in 2013 
(annual percentage change −1.7).
Conclusion This study has demonstrated that the 
prevalence and incidence of CTS increased over the study 
period between 1993 and 2013. Rates of surgery for 
CTS also increased over the study period; however after 
2007, the per cent of patients receiving surgery showed 
a statistically significant decline back to the rate seen in 
2004.
IntrODuCtIOn 
Carpal tunnel syndrome (CTS) is a chronic 
focal compressive neuropathy caused by the 
entrapment of the median nerve at the level 
of the carpal tunnel in the wrist.1 CTS is the 
most common presentation of the entrap-
ment neuropathies2 and is characterised 
by symptoms including paraesthesia, dyses-
thesia, sensory loss and eventually weakness 
and atrophy of the thenar muscle. Symptoms 
are usually localised to the hand but can 
spread proximally to the forearm, upper arm 
and even shoulder.3 Despite causing relatively 
localised symptoms, CTS can have substantial 
physical, psychological and economic conse-
quences.4 5 In some cases, there may be asso-
ciations with certain occupations (such as the 
care and leisure industry),6 which involve the 
overuse of the hand and wrist as well as other 
physical comorbidities including pregnancy, 
diabetes, hypothyroidism and obesity.7 
The diagnosis of CTS is generally accepted 
to be a clinical one (based on history and 
examination findings),8 although electro-
diagnostic tests are commonly requested 
to confirm the diagnosis or differentiate 
among diagnoses, especially in the presence 
of thenar atrophy and/or persistent numb-
ness or if surgical management is being 
considered.9 The treatment of CTS is usually 
defined as either surgical or conservative 
(non-surgical). Local steroid injections and 
night splinting form the mainstay of primary 
strengths and limitations of this study
 ► Provides updated epidemiological data about a 
common and bothersome condition.
 ► Set in primary care, where most cases of carpal tun-
nel syndrome present.
 ► Uses a large primary care database, generalisable to 
the UK population.
 ► Relies on the correct coding and capture of episodes 
of carpal tunnel syndrome and carpal tunnel release 
surgery.
 o
n
 19 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020166 on 19 June 2018. Downloaded from 
2 Burton CL, et al. BMJ Open 2018;8:e020166. doi:10.1136/bmjopen-2017-020166
Open access 
care interventions in CTS, as indicated by national care 
pathways.10 11 Patients with moderate, severe or deteri-
orating symptoms following conservative treatment or 
sudden and severe symptoms are recommended to be 
referred for consideration of surgery.12 Carpal tunnel 
release surgery (CTR) is routinely carried out under 
local anaesthetic as day surgery. Open and endoscopic 
approaches are used to release the flexor retinaculum.13 
Previous studies have sought to estimate the prevalence 
and/or incidence of CTS. Such epidemiological studies 
have been diverse in their approach to the populations 
studied and case definitions applied.14 The reported esti-
mates for annual prevalence range from 3720 to 5700 per 
100 000 per year15–17 and the reported incidence from 
72 to 8200 per 100 000 per year.6 14 18–23 CTS is generally 
accepted to be more common in women; the female-to-
male ratio ranges between 0.78 and 9.66.14 15 A number of 
previous studies have observed the trends of prevalence 
or incidence over time and identified an increase,19 20 24 
with 2005 being the latest data collection point. The most 
recent primary care-based study in the UK used data 
between 1992 and 2000.18
Episodes of CTR have also been shown to have 
increased, with audit data from one major tertiary UK 
Hand Centre suggesting that referral for CTR increased 
over a 10-year period from 59.7 to 112 per 100 000 popula-
tion per year between 1989–1999 and 2000–2001.25 Using 
Hospital Episode Statistics (HES) between 1998 and 
2011, Bebbington and Furniss also observed an increase 
in the absolute number of patients with CTS and episodes 
of CTR; however, they also noted a decrease in the use of 
surgery post-2008.26
Previous studies have used a range of methods to classify 
episodes of CTS and have been conducted in a number of 
population settings. CTS is essentially a clinical diagnosis, 
and in the UK, the majority of patients will first present 
to and be managed within primary care. Only a propor-
tion of these patients will be referred into more special-
ised services and since not all surgical episodes will take 
place in secondary care (hospitals), as community clinics 
are now receiving referrals, primary care records should 
capture the majority of episodes. Data from a high-quality 
source, representative of the UK population is necessary 
to support the planning and commissioning of services.
The aim of this study is therefore to provide updated 
estimates of the prevalence, incidence and surgical 
management of CTS and describe trends over a 20-year 
period, using data from a large national primary care 
database (Clinical Practice Research Datalink (CPRD)).
MethODs
This was an observational study using the CPRD to estimate 
the prevalence, incidence and surgical management of 
CTS from 1993 to 2013. CPRD is a live, primary care data-
base of anonymised medical records from general prac-
tices. It holds information of over 11.3 million patients 
from 674 practices in the UK since 1987; 4.4 million active 
(alive and currently registered) patients are currently 
contributing information to the datalink, which equates 
to 6.9% of the UK population.27 The CPRD is broadly 
representative of the UK general population in terms 
of age, gender and ethnicity.27 The CPRD has National 
Research Ethics Committee approval for observational 
research using primary care data and as such no further 
permissions were required. The Independent Scientific 
Advisory Committee study protocol 14_167 was approved 
in September 2014.
During clinical interactions, Read codes are used to 
record signs and symptoms, treatments and therapies, 
investigations, occupations, diagnoses and appliances. 
Read codes make up a hierarchical ‘thesaurus’ stored by 
the computer. Clinical information is hence stored in a 
retrievable and analysable format.28
The study population consisted of men and women over 
18 years of age. Data was used from practices which met 
a data quality standard based on continuity of recorded 
data, and from patients who had a record including at 
least their registration status, age and gender. These 
quality standards were required to have been met for at 
least 2 years prior to an incident episode and at the point 
of diagnosis for a prevalent episode.27
Prevalent and incident patients were identified by 
a consultation recorded using one of the Read codes 
listed in table 1. Some treatment codes and in the case 
of in injections, linked prescription data, were included 
as evidence of diagnosis as per previous studies.18 Pilot 
work using a local primary care database (Consultations 
in Primary Care Archive (CiPCA)29) had noted that 30% 
of CTS cases with a treatment code (ie, CTR or a coded 
carpal tunnel injection) had not initially received a diag-
nosis code. This means that at presentation, patients may 
have been attributed a more generic term such as ‘hand 
pain’ and later gone on to receive condition-specific 
treatment. Hence, treatment codes were used to capture 
such cases, which would be missed when using diagnostic 
codes only.
The prevalence of individuals consulting with CTS 
was calculated per annum. The numerator for preva-
lence was the number of patients with a record of a CTS 
diagnosis or evidence of an episode of CTR or a carpal 
tunnel injection (CTI), in each calendar year. In order 
to determine annual incidence, the numerator was the 
Table 1 Read codes used to define a prevalent or incident 
episode of carpal tunnel syndrome
Term Read code
Carpal tunnel syndrome F340
Injection of carpal tunnel 85BE.00
Carpal tunnel release 70560
Endoscopic carpal tunnel 
release
7056011
Carpal tunnel decompression 70564
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number of patients with a record of CTS or evidence of 
CTR or CTI, without a prior record of these codes during 
a run-in period of 2 years. This 2-year run-in period was 
based on expert consensus with the aim of estimating the 
period of time during which a new episode of CTS may 
develop. It was felt unlikely that a patient with ongoing 
bothersome symptoms would not have presented in 
primary care within this 2-year period. This however is an 
assumption made in order to define incident cases in this 
data set. It remains possible that patients had CTS in the 
community and did not present, presented in an alterna-
tive setting or indeed had a misdiagnosis/uncoded diag-
nosis made. CTS could present as a new episode in the 
contralateral wrist sometime after the initial presentation, 
hence it was not felt possible to define this criterion as 
‘no previous recorded episode’. All incidence patients 
were therefore required to have complete registration 
for this two calendar years prior to the event date. Pilot 
work in CiPCA had shown that over 9 years observed, 4% 
of potential incident cases were lost due to the lack of 
2 years registration data required to define an incident 
episode.
The denominator population for calculation of preva-
lence was the total up-to-standard person-years contrib-
uted to CPRD by patients over the age of 18 years, for 
each annual period between 1993 and 2013. In order 
to apply the same criteria to both the numerator and 
denominator populations, the denominator populations 
for calculating incidence were also required to have regis-
tration at the mid-point of the year, two calendar years 
before the index year.
Episodes of CTR were identified using Read codes as 
shown in table 2. In addition, codes used to define ‘rere-
lease of carpal tunnel’ and ‘revision of carpal tunnel 
release’ were included as a surgical episode (if first 
recorded). These terms were not included in the defini-
tion of CTS for the estimation of prevalence and incidence 
as they may not have indicated an episode of ‘idiopathic’ 
CTS but rather iatrogenic symptoms following previous 
(unsuccessful) surgery. Of note, revision codes contrib-
uted 1.00% of the total surgical codes used. Results were 
expressed as the percentage of patients with a preva-
lent episode of CTS having a code of CTR in the same 
calendar year. Percentages were calculated based on the 
number of prevalent cases as opposed to incident cases as 
it was felt likely that patients would receive surgery in the 
annual period following their index consultation.
statistical methods
Age-specific and sex-specific annual prevalence and inci-
dence were determined for each calendar year, between 
1993 and 2013 and presented as n/10 000 person-years. 
For CI calculation a Poisson distribution was used. As a 
sensitivity analysis, age-standardised and sex-standardised 
annual figures of CTS prevalence and incidence for each 
year were also calculated, using population estimates 
provided by the website of the Office of National Statis-
tics.30 Unstandardised and standardised rates were very 
similar, hence we report unstandardised rates as the 
primary outcome. The age-standardised and sex-stan-
dardised estimates of the annual prevalence and inci-
dence of CTS are shown in online supplementary table 1.
Episodes of CTR were identified and the frequency 
in each calendar year expressed as a percentage of the 
prevalent population for the same time period. Emerging 
trends were described. Joinpoint regression was used to 
determine mean annual percentage change (APC) and 
assess when significant changes (‘Joinpoints’) occurred 
in the underlying trend for incidence, prevalence and 
surgery. This method assists the exploration of the poten-
tial influence of changes in practice, although such 
potential associations cannot be proven.31 32 Models were 
fitted using the Joinpoint Regression Program (V.4.3.1.0) 
and the best fitting model chosen (up to five Joinpoints).
Patient and public involvement
Patients were not directly involved in the design of this 
study; however, the results will be used to inform discus-
sions regarding further research in this field with our 
local Research User Group.
results
trends in prevalence
Table 3 presents the prevalence (crude estimates) of 
patients presenting in primary care with CTS between 
1993 and 2013 and the demographics of the population. 
The denominator population for prevalence increased 
from 1 117 433 person-years in 1993 to 3 473 094 person-
years in 2013. The total prevalence in 1993 was 26.03 
per 10 000 person-years (95% CI 25.10 to 27.00), and 
for 2013, 36.08 per 10 000 person-years (95% CI 35.45 to 
36.72). As shown in figure 1 and corresponding table 4, 
prevalence appeared to decrease between 1993 and 2000 
(APC=−0.8%, 95% CI −2.6 to 1.0). It then increased 
between 2000 and 2004 (APC=7.8%, 95% CI 3.1 to 12.7) 
and then increased at a slower rate between 2004 and 
2013 (APC=1.1%, 95% CI 0.4 to 1.8). The female-to-male 
ratio reduced over time from 2.74 in 1993 to 1.93 in 2013. 
The median age of female and male patients with CTS 
increased from 49 and 53 years, respectively in 1993 to 
54 and 59 years, respectively in 2013 (see online supple-
mentary table 2). Online supplementary table 3 and 
Table 2 Read codes used to define a surgical episode
Term Read code
Carpal tunnel release 817
Rerelease of carpal tunnel 16896
Endoscopic carpal tunnel 
release
39335
Revision of carpal tunnel 
release
97195
Carpal tunnel decompression 19249
 o
n
 19 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020166 on 19 June 2018. Downloaded from 
4 Burton CL, et al. BMJ Open 2018;8:e020166. doi:10.1136/bmjopen-2017-020166
Open access 
supplementary figures 1 and 2 further illustrate the crude 
prevalence of CTS over time by age and gender. The prev-
alence of CTS appears to increase with age in the male 
population, whereas the prevalence in women peaks in 
the 50–59 years age group, dips in the 60–69 years age 
group and then peaks once more in the 70+ years age 
group.
trends in incidence
Table 5 presents the annual incidence (crude estimates) 
for patients presenting in UK primary care with carpal 
tunnel syndrome between 1993 and 2013 and the demo-
graphics of the population. The denominator population 
for incidence, which is dependent on patients having 2 
years up to standard data prior to the mid-point of the 
year in question, increased from 783 330 person-years in 
1993 to 3 015 670 person-years in 2013. The crude inci-
dence in 1993 was 20.22 per 10 000 person-years (95% CI 
19.24 to 21.24), and for 2013, 27.68 per 10 000 person-
years (95% CI 27.09 to 28.28). As shown in figure 2 and 
table 6, the results of the best fitting Joinpoint regression 
suggest the incidence increased between 1993 and 2000 
(APC=0.3, 95% CI −2.3 to 2.9). It then increased more 
quickly between 2000 and 2004 (APC=6.9, 95% CI 0.5 to 
13.7), before slowing between 2004 and 2013 (APC=0.7. 
95% CI −0.2 to 1.6). The female-to-male ratio reduced 
over time from 2.57 in 1993 to 1.88 in 2013. The median 
age of female and male patients were noted to increase 
from 50 and 51 years, respectively in 1993 to 55 and 59 
years, respectively in 2013 (see online supplementary 
table 4). See online supplementary table 5 and supple-
mentary figures 3 and 4 further illustrate the incidence 
of CTS over time by age and gender. As with prevalence, 
the incidence of CTS appears to increase with age in the 
male population, whereas the prevalence in women peaks 
in the 50–59 years age group, dip in the 60–69 years age 
group and then peak once more in the 70+ years age 
group.
trends in the percentage of patients with carpal tunnel 
syndrome receiving surgical management
Table 7 presents the percentage of prevalent patients with 
a recorded episode of CTR in each calendar year between 
1993 and 2013 and the demographics of this sample. The 
percentage of all patients with a recorded episode of CTR 
in 1993 was 19.35%, and for 2013, 27.41%. As shown in 
figure 3 and corresponding table 8, the percentage of 
patients with a coded episode of CTR increased between 
1993 and 2007 (APC=2.6, 95% CI 1.9 to 3.2). It then 
appeared to decrease between 2007 and 2013 (APC=−1.7, 
95% CI −3.3 to −0.3). The median age of females and 
males receiving CTR were noted to increase from 53 and 
Table 3 Crude prevalence of carpal tunnel syndrome (n/10 000 person-years) per calendar year, as presented in UK primary 
care (Clinical Practice Research Datalink)
Year
Number 
of person-
years
Prevalent 
individuals
Total crude prevalence 
per 10 000 person-years, 
(95% CI)
Female prevalence per 
10 000 person-years, 
(95% CI)
Male prevalence per 
10 000 person-years, 
(95% CI) Female:male
1993 1 117 443 2909 26.03 (25.10 to 27.00) 37.52 (35.96 to 39.13) 13.69 (12.72 to 14.71) 2.74
1994 1 198 256 3188 26.61 (25.69 to 27.55) 37.23 (35.73 to 38.79) 15.21 (14.23 to 16.25) 2.45
1995 1 286 800 3343 25.98 (25.11 to 26.88) 36.64 (35.20 to 38.12) 14.58 (13.65 to 15.56) 2.51
1996 1 437 567 3706 25.78 (24.96 to 26.62) 36.75 (35.38 to 38.16) 14.09 (13.23 to 15.00) 2.61
1997 1 681 756 4190 24.91 (24.17 to 25.68) 34.87 (33.64 to 36.14) 14.34 (13.53 to 15.18) 2.43
1998 1 899 393 4884 25.71 (25.00 to 26.45) 36.57 (35.38 to 37.79) 14.22 (13.46 to 15.01) 2.57
1999 2 289 158 5696 24.88 (24.24 to 25.54) 35.21 (34.14 to 36.30) 14.01 (13.32 to 14.72) 2.52
2000 2 787 457 6998 25.11 (24.52 to 25.70) 34.82 (33.86 to 35.81) 14.90 (14.26 to 15.57) 2.34
2001 3 057 458 8137 26.61 (26.04 to 27.20) 36.46 (35.52 to 37.42) 16.31 (15.67 to 16.98) 2.23
2002 3 385 511 9722 28.72 (28.15 to 29.29) 39.33 (38.40 to 40.28) 17.64 (17.00 to 18.29) 2.23
2003 3 552 908 11 124 31.31 (30.73 to 31.90) 43.61 (42.66 to 44.59) 18.53 (17.90 to 19.18) 2.35
2004 3 712 172 12 622 34.00 (33.41 to 34.60) 47.20 (46.23 to 48.19) 20.33 (19.68 to 20.99) 2.32
2005 3 808 183 12 741 33.46 (32.88 to 34.04) 46.37 (45.42 to 47.34) 20.09 (19.45 to 20.74) 2.31
2006 3 857 487 12 718 32.97 (32.40 to 33.55) 45.82 (44.88 to 46.78) 19.69 (19.07 to 20.33) 2.33
2007 3 904 068 13 222 33.87 (33.29 to 34.45) 46.35 (45.41 to 47.31) 20.99 (20.35 to 21.65) 2.21
2008 3 897 624 14 030 36.00 (35.40 to 36.60) 49.12 (48.15 to 50.11) 22.46 (21.79 to 23.14) 2.19
2009 3 894 989 14 500 37.23 (36.60 to 37.81) 50.68 (49.69 to 51.68) 23.35 (22.68 to 24.05) 2.17
2010 3 842 773 14 166 36.86 (36.26 to 37.48) 49.75 (48.76 to 50.75) 23.57 (22.88 to 24.27) 2.11
2011 3 769 676 13 529 35.89 (35.29 to 36.50) 47.98 (47.00 to 48.97) 23.36 (22.67 to 24.07) 2.05
2012 3 714 877 13 388 36.04 (35.43 to 36.66) 47.57 (46.59 to 48.56) 24.05 (23.35 to 24.78) 1.98
2013 3 473 094 12 532 36.08 (35.45 to 36.72) 47.19 (46.18 to 48.21) 24.49 (23.75 to 25.25) 1.93
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55 years, respectively in 1993 to 57 and 62 years, respec-
tively in 2013.
DIsCussIOn
While the prevalence and incidence of CTS have 
increased over the study period 1993–2013, results 
show that episodes of surgery, increased until 2007 and 
declined thereafter.
Online supplementary tables 6 and 7 summarise esti-
mates of the prevalence, incidence and sex ratios of CTS 
from a previous scoping review of literature pertaining 
to the general population, demonstrating the substantial 
variation in results between studies, which may partly be 
the results of differences in definition of CTS applied and 
population observed. Studies which also used primary 
care data showed a similar estimate of the incidence of 
CTS in a UK primary care population18 and similarly 
reported an increase in incidence over time, although 
in a Dutch primary care population.21 As described in 
previous studies, CTS shows a peak in prevalence and 
incidence in women of middle age (50–59 years age 
group, likely due to hormonal changes around the time 
of the menopause),18 while in the male population, the 
prevalence and incidence of CTS increased with age. 
Gelfman et al also commented that an increasing number 
of older people presenting with CTS had been noted over 
the course of their study.20 The increase in the prevalence 
and incidence of CTS in the older-aged male groups, may 
partially account for the observed decrease in the female-
to-male ratio, over time.
The variability in the case definition of CTS was high-
lighted by Descatha et al,33 who identified seven case 
definitions of CTS proposed for use in population-based 
studies. Definitions included variations of symptoms 
Figure 1 Joinpoint analysis of the crude prevalence of carpal tunnel syndrome between 1993 and 2013. ^, reflects significance 
at the 0.05 level; APC, annual percentage change. 
Table 4 Joinpoint analysis of crude prevalence
Segment
Lower 
end point
Upper 
end point
Annual 
percentage 
change Lower 95th CI Upper 95th CI
Test
statistic (t) Prob > |t|
1 1993 2000 −0.8 −2.6 1.0 −1.0 0.3
2 2000 2004 7.8* 3.1 12.7 3.7 0.0
3 2004 2013 1.1* 0.4 1.8 3.4 0.0
*Reflects significance at the 0.05 level.
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only; symptoms and examination findings; symptoms and 
either physical examination or electrodiagnostic results 
and symptoms and electrodiagnostic results. This study 
showed a range in the population prevalence of CTS 
from 2.5% to 11%, with studies using less specific case 
definitions yielding higher prevalence rates.33 Misclassi-
fication ranged between 1% and 10%. The prevalence 
of CTS in any given population is likely therefore to 
depend on the definition of CTS applied. The case defi-
nition in our study is derived from general practitioner 
(GP)-recorded diagnosis and treatment codes, which 
may have been based on clinical findings alone; those 
who have had further investigations and those who have 
received definitive condition-specific treatment. Hence, 
it uses a pragmatic approach, across a large population 
that will include all patients presenting to their GP with 
symptoms. Our study methods do however assume that 
patients with symptoms will be presenting in primary care 
or be receiving definitive coded treatment. The study will 
not capture patients with chronic symptoms who are not 
presenting in primary care or who had a coded episode of 
surgery or injection.
Although Joinpoint analysis does not provide evidence 
for the cause of a change in observed outcomes, it high-
lights when a significant change in trend has taken place. 
Our results suggest that the annual percentage change 
in prevalence and incidence was highest between 2000 
and 2004. A possible reason for this may be the publi-
cation of the UK Government’s information technology 
strategy for the NHS in 1998,34 which proposed that by 
2005, the person-based electronic health record (HER), 
would have been fully implemented.35 Although no direct 
evidence for this was found, it may be possible that with the 
increasing use of IT systems in primary care and attention 
to providing Read codes for each consultation, episodes 
of CTS were more frequently and accurately recorded. 
This would not however explain the continuing increase 
of the incidence in CTS post-2005.
Between 2000 and 2004, the Government implemented 
the second phase of its ‘War on Waiting’, that is, the reduc-
tion of waiting times. For example, the maximum wait for 
a day-case procedure (eg, a CTR) was reduced from 18 
months to 6 months.36 The peak in prevalence of CTS 
(with our definition partly based also on treatment codes, 
which in 2013 constituted 29.36% of prevalent patients) 
observed in 2004 may therefore be partly explained by 
the fact that patients requiring surgery were ‘accumu-
lating’ between 2000 and 2004 and subsequently received 
definitive treatment. This effect would however not be 
expected to impact so heavily on the incidence, which 
Table 5 Crude incidence of carpal tunnel syndrome (n/10 000 person-years) per calendar year, as presented in UK primary 
care (Clinical Practice Research Datalink)
Year
Number 
of person-
years
Incident 
individuals
Total crude incidence per 
10 000 person-years
(95% CI)
Female incidence per 
10 000 person-years 
(95% CI)
Male incidence per 
10 000 person-years 
(95% CI) Female:male
1993 783 330 1584 20.22 (19.24 to 21.24) 28.72 (27.09 to 30.42) 11.17 (10.14 to 12.29) 2.57
1994 868 616 1797 20.69 (19.74 to 21.67) 28.52 (26.97 to 30.13) 12.38 (11.34 to 13.69) 2.30
1995 1 003 593 1963 19.56 (18.70 to 20.45) 27.53 (26.12 to 29.00) 11.12 (10.20 to 12.10) 2.48
1996 1 065 068 2142 20.11 (19.27 to 20.98) 28.39 (27.00 to 29.84) 11.37 (10.47 to 12.33) 2.50
1997 1 150 299 2306 20.05 (19.24 to 20.88) 28.39 (27.05 to 29.79) 11.25 (10.39 to 12.16) 2.52
1998 1 300 074 2696 20.74 (19.95 to 21.52) 29.65 (28.57 to 31.22) 11.37 (10.56 to 12.23) 2.61
1999 1 497 673 3030 20.23 (19.52 to 20.10) 28.53 (27.35 to 29.75) 11.54 (10.77 to 12.34) 2.47
2000 1 682 027 3462 20.58 (19.90 to 21.28) 28.66 (27.54 to 29.81) 12.15 (11.41 to 12.93) 2.36
2001 2 019 596 4391 21.74 (21.10 to 22.40) 29.72 (28.68 to 30.79) 13.46 (12.74 to 14.20) 2.21
2002 2 456 761 5718 23.27 (22.68 to 31.78) 31.78 (30.78 to 32.79) 14.47 (13.80 to 15.17) 2.20
2003 2 669 111 6772 25.37 (24.77 to 25.98) 35.13 (34.14 to 36.14) 15.33 (14.67 to 16.02) 2.29
2004 2 779 821 7868 28.30 (27.68 to 28.94) 39.22 (38.19 to 40.27) 17.10 (16.42 to 17.81) 2.29
2005 3 164 506 8113 25.64 (25.08 to 26.20) 35.55 (34.63 to 36.48) 15.49 (14.88 to 16.12) 2.30
2006 3 307 051 8337 25.21 (24.67 to 25.76) 34.91 (34.02 to 35.82) 15.27 (14.68 to 15.89) 2.29
2007 3 343 009 8865 26.52 (25.97 to 27.08) 35.76 (34.86 to 36.67) 17.07 (16.45 to 17.71) 2.09
2008 3 341 299 9437 28.24 (27.68 to 28.82) 38.23 (37.30 to 39.17) 18.06 (17.42 to 18.72) 2.12
2009 3 383 196 9918 29.32 (28.74 to 29.90) 39.73 (38.79 to 50.68) 18.69 (18.04 to 19.36) 2.13
2010 3 357 338 9634 28.70 (28.13 to 29.27) 38.70 (37.77 to 39.64) 18.46 (17.82 to 19.13) 2.10
2011 3 269 296 9083 27.78 (27.21 to 28.36) 37.11 (36.19 to 38.05) 18.20 (17.54 to 18.87) 2.04
2012 3 222 880 9011 27.96 (27.39 to 28.54) 36.44 (35.52 to 37.88) 19.23 (18.56 to 19.93) 1.89
2013 3 015 670 8346 27.68 (27.09 to 28.28) 35.95 (35.01 to 36.92) 19.12 (18.43 to 19.84) 1.88
 o
n
 19 June 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020166 on 19 June 2018. Downloaded from 
7Burton CL, et al. BMJ Open 2018;8:e020166. doi:10.1136/bmjopen-2017-020166
Open access
disregards repeat patient presentations in subsequent 
annual periods, unless patients with a less specific code 
received treatment and appeared as an incident case. The 
introduction of the 18-week target of time from referral to 
treatment in 2008 did not seem to have a similar impact 
on estimates of prevalence or incidence of CTS, which 
makes it less certain to what extent these policy changes 
may have influenced our results. There are likely to be 
further reasons behind the observed changes.
The change in trends of 2004 may also represent a 
change in service. The introduction of the Quality and 
Outcome Framework (QOF) occurred with the advent of 
the General Medical Services contract in 2004. Although 
there has never been a musculoskeletal health domain, 
the importance of coding to maintain registers and 
evidence of outcomes in line with QOF may have influ-
enced coding behaviour.
At the same time as QOF, Primary Care Trusts (PCTs) 
were given a role in commissioning services. The ability 
of PCTs to commission new services heralded the devel-
opment of the Musculoskeletal Interface Clinics (MIC), 
which act as a ‘one stop shop’ for patients with musculo-
skeletal problems. A referral to this clinic from primary 
care may also be a reason prevalent patients with persisting 
symptoms stopped presenting in primary care.
These three factors (improved coding, service redevel-
opment and a reduction in waiting times) may all partly 
explain the change in incidence and prevalence of CTS 
between 2000 and 2004 but are unlikely to fully explain 
the observed trends. Further factors of potential influ-
ence may include the increasing rates of risk factors of 
CTS such as diabetes and obesity.37 38 While standardising 
the prevalence and incidence by age and gender did not 
change the overall picture of the changing trends, online 
Figure 2 Joinpoint analysis of the crude incidence of carpal tunnel syndrome between 1993 and 2013. ^, reflects significance 
at the 0.05 level; APC, annual percentage change.
Table 6 Joinpoint analysis of crude incidence
Segment
Lower 
end point
Upper 
end point
Annual 
percentage 
change Lower 95th CI Upper 95th CI
Test
statistic (t) Prob > |t|
  1 1993 2000 0.3 −2.3 2.9 0.2 0.8
  2 2000 2004 6.9* 0.5 13.7 2.3 0.0
  3 2004 2013 0.7 −0.2 1.6 1.7 0.1
*Reflects significance at the 0.05 level.
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supplementary figure 1 suggests that the prevalence of 
CTS increased most obviously in the male and female 
over 70 years age groups.
The Joinpoint analysis suggested an increase in surgical 
management of CTS between 1993 and 2007 (APC=2.55), 
followed by a reducing trend between 2007 (95% CI 2004 
to 2009) and the end of the study in 2013 (APC=−1.72).
Previous studies have described the epidemiology and 
the rates of CTR in the UK. This study provides updated 
data observing the presenting primary care population. 
Using data from the General Practice Research Database 
(GPRD) (forerunner to CPRD), Latinovic et al reported 
that 31% of patients with CTS had surgery in 2000,18 
which is similar to the 25.5% found in our study at the 
same time point. The small difference between the esti-
mates may be the result of a difference in the calculation 
used to derive the denominator population. Audit data 
from one tertiary hand centre, Wildin et al also showed 
that the rate of referrals for CTR surgery had increased 
over the 10 years between 1989–1999 and 2000–2001.25 
Furthermore, Bebbington and Furniss observed demo-
graphic population shifts in hand conditions including 
CTS within HES, which record diagnoses and procedures 
performed within the National Health Service (NHS) 
Hospitals in England. They used linear regression to 
predict future trends in hand surgery, showing that while 
absolute numbers of CTS diagnoses and CTR procedures 
increased between 1998 and 2011, the pre-2008 increase 
in CTR was significantly steeper than the post-2008 
slope (p<0.001).26 This is suggestive of a decrease in the 
surgical management of CTS in terms of the proportion 
of patients with CTS having an operation, but not neces-
sarily in the numbers of surgical episodes in absolute 
terms, which Bebbington and Furniss predict will have 
increased by 99% (95% CI 65 to 132) in 2030 compared 
with 2011.26 The data from CPRD however, suggested a 
reduction in both real-term episodes of CTR as well as 
the proportion of the (increasing) prevalent population 
receiving surgical treatment.
We may speculate regarding potential reasons for 
the initial increase in surgical management of CTS, 
for example, increased access to specialist services (eg, 
community-based MIC), increased litigation leading to 
more definitive treatments being sought and increased 
patient expectations and demand, but we have no 
evidence for such explanations.
The decreasing trend in the use of CTR post-2007 is 
likely to be multifactorial; however, the changing structure 
of the NHS and its funding streams may have influenced 
the observed trend. Around 2007–2008, practice-based 
Table 7 Percentage of patients with carpal tunnel syndrome with a recorded episode of carpal tunnel release surgery per 
calendar year, as presented in UK primary care (Clinical Practice Research Datalink)
Year
Episodes per 
10 000 person-
years
% prevalent 
individuals having 
surgery
% prevalent 
females having 
surgery
% prevalent 
males having 
surgery
Female median 
age (25%–75% IOR)
Male median 
age (25%–75% IQR)
1993 5.04 19.35 18.78 21.03 53 (43–64) 55 (44–69)
1994 5.70 21.42 20.62 23.52 53 (43–68) 58 (45–70)
1995 6.19 23.81 23.40 24.92 53 (42–67) 55 (44–70)
1996 5.41 20.99 20.48 22.43 53 (44–65) 52 (40–65)
1997 5.70 22.89 22.14 24.81 53 (45–67) 56 (42–69)
1998 5.73 22.28 21.28 25.00 53 (44–65) 53 (44–65)
1999 6.24 25.09 24.60 26.38 54 (44–67) 56 (46–70)
2000 6.41 25.54 24.84 27.23 54 (44–68) 56 (45–69)
2001 6.88 25.87 25.95 25.68 55 (45–68) 58 (46–71)
2002 7.02 24.46 24.19 25.09 57 (46–71) 55 (45–68)
2003 8.26 26.39 25.88 27.66 56 (45–67) 57 (46–71)
2004 9.34 27.48 27.38 27.74 56 (46–67) 57 (47–68)
2005 9.70 29.00 28.31 30.65 57 (47–68) 58 (46–71)
2006 9.36 28.40 28.31 28.61 57 (47–68) 60 (48–72)
2007 9.71 28.66 28.26 29.59 56 (46–69) 59 (48–71)
2008 10.53 29.25 29.00 29.82 56 (46–68) 60 (49–72)
2009 10.92 29.32 28.73 30.66 56 (46–70) 61 (49–72)
2010 10.40 28.22 27.57 29.62 57 (47–71) 61 (48–73)
2011 9.47 26.37 26.11 26.93 57 (47–70) 61 (49–73)
2012 9.48 26.31 25.89 27.19 57 (47–71) 60 (49–73)
2013 9.89 27.41 26.47 29.30 57 (48–70) 62 (51–74)
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commissioning was being introduced. This gave primary 
care notional budgets with which to purchase care for 
their patients with the aim of aligning clinical and finan-
cial responsibility. Restricting access to certain procedures 
including CTR, by implementing prespecified criteria, 
was one way to help achieve this, which may have resulted 
in a reduction in the use of CTR.
There are a number of limitations associated with the 
data in this study. The accuracy of consultation data is 
dependent on the validity of the computerised informa-
tion it uses. In a review of 212 publications which aimed 
to validate diagnoses recorded in GPRD data, Herrett 
et al reported that the median proportion of cases with 
a confirmed diagnosis was 89% (range 24%–100%), 
but the majority of publications did not present the 
sensitivity of a coded diagnosis, which means that infor-
mation regarding the proportion of missed cases is 
lacking. Potential misclassification; non-attendance 
in primary care; variation in between GP coding and a 
lack of coding may all lead to an unmeasured shortfall 
in observed cases.27 39 This study relies on the diagnosis 
of CTS to be correct and the subsequent coding to be 
precise. While CTS diagnoses have not been validated, 
in a study comparing musculoskeletal diagnoses in four 
different databases, Jordan et al suggested that musculo-
skeletal coding in GPRD was less reliable than in its other 
healthcare datasets including CiPCA.40 We took measures 
to reduce the effect of miscoding (eg, including surgery 
and injection codes in prevalence measures, if diagnostic 
codes had not been used), but it is possible that results 
will not be entirely representative of the true prevalence 
and incidence of CTS.
Given the lack of clarity in the accuracy of coding 
and the likelihood that associated clinical encounters 
following a CTR were coded using a surgical code, only 
the first surgical code could reliably be used to indicate an 
Figure 3 Joinpoint analysis of the percentage of prevalent patients with a recorded episode of carpal tunnel release, in each 
calendar year syndrome, between 1993 and 2013. ^, reflects significance at the 0.05 level; APC, annual percentage change. 
Table 8 Joinpoint analysis of the use of surgery
Segment
Lower 
end point
Upper 
end point
Annual 
percentage 
change Lower 95th CI Upper 95thCI
Test statistic 
(t) Prob > |t|
1 1993 2007 2.6* 1.9 3.2 8.2 0.0
2 2007 2013 −1.7* −3.1 −0.3 −2.6 0.0
*Reflects significance at the 0.05 level.
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episode of surgery. This is likely to have led to an underes-
timation of surgical episodes being identified as episodes 
on the contralateral hand will have been automatically 
discounted as they were undistinguishable. Furthermore, 
prevalence and incidence were similarly likely to have 
been underestimated as repeat presentations for the ipsi-
lateral hand are indistinguishable from presentations in 
the contralateral hand.
While CPRD provides a large generalisable sample, 
which has substantial benefits when estimating epide-
miological trends, it cannot directly measure patient-re-
ported outcomes. Furthermore, surgery can be seen as 
a ‘gold standard’ treatment, but it does not necessarily 
signify cure. A review of the surgical treatment of CTS 
reported that 70%–90% of patients undergoing a CTR 
have a good outcome (definitions varied).41 In a retro-
spective cohort study over a mean follow-up of 13 years 
postsurgery, 88% of patients were either completely satis-
fied or very satisfied with surgery. Seventy-four per cent 
reported their symptoms had completely resolved; 1.8% 
(113 patients) had undergone repeat surgery.42 There is 
little evidence however that CTR is an appropriate initial 
management option for patients presenting to primary 
care with mild-to-moderate symptoms, especially in the 
absence of high-quality trial evidence that conservative 
management is ineffective.43 44
Future research in this field could describe the charac-
teristics of patients presenting with CTS in greater detail, 
and observe course and prognosis of CTS in primary 
care. It may then be possible to identify predictors of the 
outcome of primary care management, and potentially 
identify patients requiring surgery.
COnClusIOn
An increase in the incidence and prevalence of CTS is 
likely to lead to an increased demand on services and cost 
to the healthcare economy.26 This study has demonstrated 
an increase in the prevalence and incidence of physician 
diagnosed CTS over the study period between 1993 and 
2013. Rates of referral for CTS and surgical intervention 
have also increased over the study period; however in the 
later years of the study, the per cent of patients receiving 
surgery has begun to decline .
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